Tentarix Biotherapeutics
tentarix.com
Biotechnology
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Latest round
Series B
Sep 2023 · 3 yr ago
Backers
1
Amplitude Ventures
The money's age
Long since its last round
37 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 23, 2024
New executive Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO · businesswire.com
Sep 4, 2023
Raised a round Series B
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Sep 2023 | — | — | businesswire.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Amplitude Ventures Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Valora Therapeutics is developing AbLec™ multispecific antibodies and T-Lec™ T cell engagers — antibody-engineering platforms that decoy…
About Elpiscience is a clinical-stage biopharmaceutical company dedicated to the development of innovative immunotherapies for oncology and…
Boomerang Medical is a bioelectronic medicine company targeting autoimmune diseases.
Avenzo Therapeutics is a clinical-stage biotechnology company that develops next-generation targeted oncology therapies. It was co-founded…
Logic gated immunotherapies for cancer and autoimmune disease. Synolo Therapeutics is advancing a new class of therapeutics for cancer.
Advanced Treg Therapy for Autoimmune Diseases. For more information, contact [email protected].
News
Tentarix Biotherapeutics Strengthens Executive Team
SAN DIEGO, September 30, 2025--Tentarix Biotherapeutics LP, a biotechnology company developing best-in-class, targeted and conditionally active multispecific biologics, today announced four key executive changes that further strengthen its executive team
Read more
Report
Report
AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology
NORTH CHICAGO, Ill. and SAN DIEGO, Feb. 22, 2024/ PRNewswire/-- AbbVie Inc. and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in onc
Read more
Report
AbbVie (ABBV) and Tentarix Collaborate Over Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology
Read more
Report
Financials
Latest round
Series B
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series B | 2023 | — | Details |